These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16481897)

  • 21. Caregiver opinions about fragile X population screening.
    Bailey DB; Bishop E; Raspa M; Skinner D
    Genet Med; 2012 Jan; 14(1):115-21. PubMed ID: 22237440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prenatal diagnosis and carrier screening for fragile X by PCR.
    Brown WT; Nolin S; Houck G; Ding X; Glicksman A; Li SY; Stark-Houck S; Brophy P; Duncan C; Dobkin C; Jenkins E
    Am J Med Genet; 1996 Jul; 64(1):191-5. PubMed ID: 8826474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An assessment of screening strategies for fragile X syndrome in the UK.
    Pembrey ME; Barnicoat AJ; Carmichael B; Bobrow M; Turner G
    Health Technol Assess; 2001; 5(7):1-95. PubMed ID: 11262423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implementing Group Prenatal Counseling for Expanded Noninvasive Screening Options.
    Gammon BL; Otto L; Wick M; Borowski K; Allyse M
    J Genet Couns; 2018 Aug; 27(4):894-901. PubMed ID: 29247311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Wide scope prenatal diagnosis at Kuopio University Hospital 1997-1998: integration of gene tests and fetal karyotyping.
    Kallinen J; Marin K; Heinonen S; Mannermaa A; Palotie A; Ryynänen M
    BJOG; 2001 May; 108(5):505-9. PubMed ID: 11368137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic screening and counseling.
    Norton ME
    Curr Opin Obstet Gynecol; 2008 Apr; 20(2):157-63. PubMed ID: 18388816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic counseling for fragile x syndrome: updated recommendations of the national society of genetic counselors.
    McConkie-Rosell A; Finucane B; Cronister A; Abrams L; Bennett RL; Pettersen BJ
    J Genet Couns; 2005 Aug; 14(4):249-70. PubMed ID: 16047089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility and acceptance of screening for fragile X mutations in low-risk pregnancies.
    Ryynänen M; Heinonen S; Makkonen M; Kajanoja E; Mannermaa A; Pertti K
    Eur J Hum Genet; 1999; 7(2):212-6. PubMed ID: 10196705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Screening for fragile X syndrome. International experiences].
    Vuust J; Larsen LA; Grønskov K; Nørgaard-Pedersen B; Brøndum-Nielsen K
    Ugeskr Laeger; 2006 Oct; 168(43):3704-9. PubMed ID: 17069733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carrier diagnosis of the fragile X syndrome--a challenge in antenatal clinics.
    Ryynänen M; Kirkinen P; Mannermaa A; Saarikoski S
    Am J Obstet Gynecol; 1995 Apr; 172(4 Pt 1):1236-9. PubMed ID: 7726262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic evaluation of prenatal carrier screening for fragile X syndrome.
    Vintzileos AM; Ananth CV; Fisher AJ; Smulian JC; Day-Salvatore D; Beazoglou T; Knuppel RA
    J Matern Fetal Med; 1999; 8(4):168-72. PubMed ID: 10406300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prenatal genetic carrier testing using triple disease screening.
    Eng CM; Schechter C; Robinowitz J; Fulop G; Burgert T; Levy B; Zinberg R; Desnick RJ
    JAMA; 1997 Oct; 278(15):1268-72. PubMed ID: 9333269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Should all pregnant women be offered carrier testing for fragile X syndrome?
    Finucane B
    Clin Obstet Gynecol; 1996 Dec; 39(4):772-82. PubMed ID: 8934029
    [No Abstract]   [Full Text] [Related]  

  • 34. Economic evaluation of prenatal population screening for fragile X syndrome.
    Hollingsworth B; Harris A
    Community Genet; 2005; 8(2):68-72. PubMed ID: 15925881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Informing members of families affected by fragile X syndrome of this diagnosis].
    Carrasco M
    Rev Neurol; 2001 Oct; 33 Suppl 1():S37-41. PubMed ID: 12447818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D; Langlois S; Douglas Wilson R; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of prenatal population-based fragile X carrier screening.
    Musci TJ; Caughey AB
    Am J Obstet Gynecol; 2005 Jun; 192(6):1905-12; discussion 1912-5. PubMed ID: 15970847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of fragile X pre-mutation carriers in the Chinese obstetric population using a robust FMR1 polymerase chain reaction assay: implications for screening and prenatal diagnosis.
    Cheng YK; Lin CS; Kwok YK; Chan YM; Lau TK; Leung TY; Choy KW
    Hong Kong Med J; 2017 Apr; 23(2):110-6. PubMed ID: 28253484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening for fragile X syndrome.
    Murray J; Cuckle H; Taylor G; Hewison J
    Health Technol Assess; 1997; 1(4):i-iv, 1-71. PubMed ID: 9414543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Attitudes Toward and Uptake of Prenatal Genetic Screening and Testing in Twin Pregnancies.
    Reese KM; Czerwinski J; Darilek S; Johnson A; Jones M; Singletary CN
    J Genet Couns; 2018 Sep; 27(5):1238-1247. PubMed ID: 29525932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.